Harmony Biosciences Holdings, Inc.

HRMY Healthcare Biotechnology

Harmony Biosciences Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $868.5 million, up 21.5% from fiscal 2024. In the quarter to June 2026, revenue grew 30.3%, EPS grew 88.4%, free cash flow grew 16.5% and total debt fell 10.5%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for five.

38.20 0.07 −0.18%
Market cap
$2.2B
P/E
12.2×
Fwd P/E
9.4×
Dividend yield
—
F-score
5/9
Altman Z
5.23
Beneish M
−2.99
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

7 5 4 4
ROE
25.93% 20.75% 17.86% 20.46%
ROA
17.38% 13.98% 12.51% 14.61%
ROIC
42.60% 50.40% 27.66% 29.70%
Return on Tangible Assets
30.10% 24.23% 25.93% 31.24%
Average Days of Receivables
44.48 40.68 43.93 42.21
Free Cash Flow per Share
5.16 6.05 5.91 6.13
Free Cash Flow
296.89 347.89 341.97 355.08
Capital Expenditures
(0.72) (0.31) — —
Other line items
Cash ROIC
17.71% 19.23% 20.00% 19.50%
Accounts Receivable Turnover
9.07 9.66 8.40 9.41
Accounts Payable Turnover
9.99 12.62 9.16 9.44
Inventory Turnover
26.70 31.60 36.15 37.87
Average Days of Payables
52.19 32.56 49.51 33.55
Days of Inventory on Hand
13.64 9.86 9.14 9.84
Tax Rate
(0.19) (0.26) (0.26) (0.25)
Research and Development Expense of Revenue
21.11% 21.83% 24.96% 23.01%
Selling, General and Administrative Expense of Revenue
29.27% 31.33% 30.51% 28.39%
Share Based Compensation of Revenue
5.45% 5.17% 4.78% 4.26%
Interest Coverage
14.74 14.23 13.49 17.12
Operating CF/Net income
1.60 2.19 2.35 1.96
Depreciation/Fixed assets
15.83 0.00 0.00 0.00
Capex/Depreciation
(0.03) (0.01) 0.00 0.00
Revenue per Share
14.35 15.11 15.55 16.57
Operating CF per Share
5.17 6.06 5.91 6.13
Capex per Share
(0.01) (0.01) 0.00 0.00
Capex to Sales
0.00 0.00 0.00 0.00

Fold the line items

Columns are period end dates